Skip to Main Content

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants. (NOOR)

Conditions

Diseases in Infants & Newborns | Infectious Diseases

Phase IIA

What is the purpose of this trial?

This study will assess the pharmacokinetics, safety, and tolerability of single and multiple doses of intravenous ceftazidime-avibactam in hospitalized infants and neonates from 26 weeks gestation to 3 months of age. In Part A of the study all patients will receive a single dose of ceftazidime-avibactam. In Part B all patients will received multiple doses of ceftazidime-avibactam. Efficacy will be assessed in the infants and neonates receiving multiple doses of ceftazidime-avibactam.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    11/12/2020
  • End Date
    12/15/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/02/2022
  • Study HIC
    #2000025063